Dispositivos de asistencia circulatoria e infecciones asociadas:nuevas terapias, nuevas complicaciones

  1. Sánchez-Ledesma, María 1
  2. González-Calle, David 2
  3. Laffond, Ana Elvira 2
  4. Villacorta-Argüelles, Eduardo 2
  5. de-la-Fuente-Aguado, Javier 3
  1. 1 Servicio de Medicina Interna, Hospital Clínico Universitario de Salamanca, Salamanca, España
  2. 2 Servicio de Cardiología, Hospital Clínico Universitario de Salamanca, Salamanca, España
  3. 3 Servicio de Medicina Interna. Hospital POVISA. Vigo (Pontevedra). España
Show affiliations +
Journal:
Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

ISSN: 2530-0792

Year of publication: 2020

Issue Title: Spanish Journal of Case Records in Internal Medicine

Volume: 5

Issue: 1

Pages: 36-38

Type: Article

DOI: 10.32818/RECCMI.A5N1A13 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Revista Española de Casos Clínicos en Medicina Interna (RECCMI)

Abstract

The use of left ventricular assist devices (LVAD) has significantly increased in the past few years. As a result, new complications, such as infections, have emerged. We present the case of the oldest LVAD carrier in our environment. Her cardiovascular disease has significantly improved, although at the cost of recurrent driveline infections and admissions to hospital. Complications associated with the implant of LVAD, such as infections, is a growing and challenging field. An outpatient and multidisciplinary approach might be the key to improve outcomes.

Bibliographic References

  • Hanff TC, Birati EY. Left ventricular assist device as destination therapy: a state of the science and art of long-term mechanical circulatory support. Curr Heart Fail Rep. 2019; 16(5): 168-179. https://doi.org/10.1007/s11897-019-00438-x.
  • Briasoulis A, Inampudi C, Akintoye E, Adegbala O, Alvarez P, Bhama J. Trends in utilization, mortality, major complications, and cost after left ventricular assist device implantation in the United States (2009 to 2014). Am J Cardiol. 2018; 121(10): 1214-1218. https://doi.org/10.1016/j.amj-card.2018.01.041.
  • Barrio A, Dobarro D, Alzola E, Raposeiras S, González-Santos JM, Sánchez PL. Durable left ventricular assist device therapy in non transplant centers in Spain: initial experience. Rev Esp Cardiol. 2020: S1885-5857(19)30408-6. https://doi.org/10.1016/j.rec.2019.09.025.
  • Siméon S, Flécher E, Revest M, Niculescu M, Roussel JC, Michel M, et al. Left ventricular assist device-related infections: a multicentric study. Clin Microbiol Infect. 2017; 23(10): 748-751. https://doi.org/10.1016/j.cmi.2017.03.008.
  • O'Horo JC, Abu Saleh OM, Stulak JM, Wilhelm MP, Baddour LM, Rizwan Sohail M. Left ventricular assist device infections: a systematic review. ASAIO J. 2018; 64(3): 287-294. https://doi.org/10.1097/MAT.0000000000000684.
  • Rose EA, Gelijns AC, Moskowitz AJ, Heitjan DF, Stevenson LW, Dembitsky W, et al. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001; 345(20): 1435-1443. https://doi.org/10.1056/NEJMoa012175.
  • Adams EE, Wrightson ML. quality of life with an LVAD: a misunderstood concept. Heart Lung. 2018; 47(3): 177-183. https://doi.org/10.1016/j.hrtlng.2018.02.003.
  • Mensa J, Soriano A, García Sánchez JE, Marco F, Letang E, Llinares P, et al. Guía terapéutica antimicrobiana. Madrid. Antares, 2020.
  • Jennings DL, Chopra A, Chambers R, Morgan JA. Clinical outcomes associated with chronic antimicrobial suppression therapy in patients with continuous-flow left ventricular assist devices. Artif Organs. 2014; 38(10): 875-879. https://doi.org/10.1111/aor.12254.
Data source: Dialnet